Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
French medtech companies are tackling diabetes and innovating, as proven by the sheer number of patents filed in 2021. Each year, the National Industrial Property Institute (INPI)ranks the top patent filers, highlighting companies that invest in innovation. The French startup PKvitality, specializing in Health and Sport Bio-wearables, is a new entrant to the prestigious ranking with the K’Watch Glucose, the first Continuous Glucose Monitor (CGM) in the form of a smartwatch, aimed at changing the daily life of millions of diabetes patients. The company, a leader in diabetes innovation, joins a ranking that includes companies from the transport sector in the top three: Safran, Stellantis and the Valeo Group.
PKvitality’s mission is to enable everyone to contribute actively to their well-being and health through products that are simple and comfortable to use. Thus, its K’Watch Glucose smartwatch will be the world’s first CGM device that will track glucose levels discreetly and continuously at the wrist.
Paris, May 16, 2022 – PKvitality, a French company specializing in Bio-wearable Health and Sports, has been selected to join the 1st promotion of Future4care, the largest eHealth accelerator in Europe.
Paris, January 28, 2022 – PKvitality, a French company specializing in bio-wearables, finalized a funding round of €6m, including an investment from the EIC Fund (European Innovation Council Fund). Other contributors to this round are Business Angels, EIT Health, alongside current investors on board, including Beurer GmbH. This round will accelerate the development of K’Watch Glucose, a Continuous Glucose Monitor (CGM) embedded in a smartwatch for diabetes patients.
Paris, November 23, 2021 – PKvitality, a French company specialized in Health and Sport bio-wearables today announced the start of a clinical study to determine the accuracy of the K’Watch Glucose. The trial is conducted with the AMCR Institute Inc, a clinical research center focused on diabetes and obesity with worldwide renown medical device expertise in the metabolic area.